Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-debate-20260406-062045-56983337_task_73907230",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Mechanistic Hypotheses: Perinatal Immune Priming and Alzheimer's Disease\n\n## Hypothesis 1: TREM2 Promoter Silencing via DNA Hypermethylation\n\n**Mechanism:** Maternal immune activation (MIA) during critical developmental windows induces DNA hypermethylation at the TREM2 promoter, creating life-long haploinsufficiency that impairs microglial amyloid clearance while preserving hyper-inflammatory responses.\n\n**Target:** TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)\n\n**Supporting Evidence:**\n- TREM2 deficiency in microglia promotes amyloid plaque compaction but increases neurotoxicity (PMID: 29101263)\n- TREM2 mutations cause Nasu-Hakola disease with late-onset neurodegeneration (PMID: 22404984)\n- Microglial epigenetic reprogramming established by early-life stress has precedent (PMID: 29382322)\n\n**Predicted Experiment:** Perform targeted bisulfite sequencing of the TREM2 promoter in sorted microglia from adult offspring exposed to poly(I:C)-induced MIA at embryonic day 12.5. Correlate methylation status with amyloid plaque coverage and microglial TREM2 protein levels via mass cytometry (CyTOF).\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation\n\n**Mechanism:** Perinatal immune activation establishes a \"super-enhancer\" landscape at NLRP3 and CASP1 loci via sustained H3K27ac deposition, lowering the threshold for inflammasome assembly decades later in response to amyloid-β or subsequent infections.\n\n**Target:** NLRP3 inflammasome axis (NLRP3, ASC, CASP1, IL-1β)\n\n**Supporting Evidence:**\n- NLRP3 is genetically associated with AD risk in genome-wide studies (PMID: 30820018)\n- Inflammasome activation is observed in AD patient brains (PMID: 26193661)\n- Monocyte \"trained immunity\" operates via H3K27ac at promoter regions (PMID: 29196501)\n\n**Predicted Experiment:** Use CUT&RUN-seq for H3K27ac mapping in CD11b+ microglia from 12-month-old mice exposed to MIA neonatally vs. controls. Challenge with amyloid-β oligomers and measure IL-1β release. Compare with aged-match non-exposed mice.\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 3: CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk\n\n**Mechanism:** Perinatal cytokines (particularly IL-6) induce lasting CpG methylation at the CX3CR1 promoter, reducing microglial CX3CR1 expression. This disrupts fractalkine (CX3CL1) signaling, impairing surveillance and removing the neuronal \"off signal,\" leading to chronic neurotoxic microglial phenotypes in aging.\n\n**Target:** CX3CL1-CX3CR1 signaling axis\n\n**Supporting Evidence:**\n- CX3CR1 deficiency in mice worsens excitotoxicity and AD pathology (PMID: 16407890, 28757878)\n- CX3CR1+ microglia show distinct regional vulnerability in AD (PMID: 30340027)\n- IL-6 can alter DNA methyltransferase activity (PMID: 22580505)\n\n**Predicted Experiment:** Cross-fostering design to separate prenatal vs. postnatal immune effects. Quantify Cx3cr1 promoter methylation in microglia from offspring at 3, 9, and 18 months. Perform 2-photon imaging of microglial process dynamics in living brain slices.\n\n**Confidence:** 0.75\n\n---\n\n## Hypothesis 4: Microglial Metabolic \"Trained Immunity\" via mTOR-HIF1α Axis\n\n**Mechanism:** Perinatal immune activation induces mTOR-dependent glycolytic reprogramming through sustained HIF1α pathway activation, establishing a life-long augmented glycolytic capacity in microglia analogous to trained innate immunity, creating hyper-inflammatory responses to amyloid-β.\n\n**Target:** mTOR-HIF1α-glycolysis pathway\n\n**Supporting Evidence:**\n- HIF1α drives glycolysis in pro-inflammatory macrophages (PMID: 20876827)\n- Microglia display metabolic shifts in AD models (PMID: 30550822)\n- Trained immunity in monocytes is mTOR-dependent (PMID: 28473586)\n\n**Predicted Experiment:** Seahorse XF96 analysis of glycolytic rate (ECAR) and oxidative phosphorylation (OCR) in microglia from MIA-exposed vs. control mice at 3, 12, and 18 months. Measure HIF1α protein levels and mTOR phosphorylation. Inhibitor studies with rapamycin or HIF1α blockers administered perinatally to establish causality.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 5: Epigenetic Dysregulation of APOE Microglial Expression\n\n**Mechanism:** Perinatal inflammation induces genotype-independent APOE overexpression in microglia via loss of repressive H3K9me3 marks at the APOE enhancer, altering amyloid clearance, lipid homeostasis, and microglial inflammatory responses throughout life.\n\n**Target:** APOE (apolipoprotein E) transcriptional regulation in microglia\n\n**Supporting Evidence:**\n- APOE ε4 is the strongest genetic AD risk factor (PMID: 24162737)\n- Microglia-specific Apoe modulates amyloid pathology (PMID: 30804518)\n- APOE expression in AD microglia is paradoxically increased (PMID: 30804518)\n\n**Predicted Experiment:** ATAC-seq combined with H3K9me3 ChIP-seq at the APOE locus in microglia from ApoE3-targeted replacement mice exposed to MIA vs. littermates. Test whether CRISPR-dCas9-mediated APOE promoter demethylation in adulthood reverses microglial phenotypes.\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 6: Microglial Replacement and Ontogeny Shift\n\n**Mechanism:** Perinatal immune activation triggers blood-brain barrier disruption facilitating monocyte infiltration and replacement of yolk-sac-derived microglia with bone marrow-derived macrophages bearing distinct transcriptomic signatures, creating a life-long altered microglial population primed for inflammation.\n\n**Target:** Microglial ontogeny and turnover; CCR2-dependent recruitment\n\n**Supporting Evidence:**\n- Peripheral monocytes can repopulate the brain under inflammatory conditions (PMID: 28602351)\n- Microglial replacement rates increase with aging (PMID: 28604728)\n- Different microglial origins yield distinct inflammatory profiles (PMID: 29909963)\n\n**Predicted Experiment:** Parabiosis or bone marrow chimera experiments with CX3CR1-GFP:CCR2-RFP reporter mice to track source and timing of microglial replacement following MIA. Single-cell RNA-seq at 3 and 18 months to quantify proportion of self-renewing vs. replaced populations.\n\n**Confidence:** 0.62\n\n---\n\n## Hypothesis 7: LncRNA-HDAC1 Complex Formation Locks Microglia in Primed State\n\n**Mechanism:** Perinatal immune activation induces a long non-coding RNA (e.g., Mirt2 or Neat1) that sequesters HDAC1 into a complex with RelA, preventing HDAC1-mediated deacetylation of NF-κB target promoters. This maintains chronic chromatin accessibility at inflammatory genes, creating irreversible \"microglial priming.\"\n\n**Target:** LncRNA-HDAC1-NF-κB regulatory axis\n\n**Supporting Evidence:**\n- LncRNAs are implicated in microglial activation (PMID: 32351397, 33376218)\n- HDAC1 regulates NF-κB-mediated inflammation (PMID: 17177989)\n- Neat1 is upregulated in AD brain tissue (PMID: 31223166)\n\n**Predicted Experiment:** RNA-seq with lncRNA targeted assembly in microglia from MIA-exposed mice. Perform MS2-RNA pull-down followed by mass spectrometry to identify HDAC1-interacting lncRNAs. Knockdown candidate lncRNAs in primary microglia and assess IL-1β and TNF-α responses to Aβ challenge.\n\n**Confidence:** 0.48\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Primary Target | Confidence |\n|---|------------|----------------|------------|\n| 1 | TREM2 DNA hypermethylation | TREM2 promoter | 0.72 |\n| 2 | NLRP3 chromatin priming | H3K27ac/NLRP3 | 0.68 |\n| 3 | CX3CR1 methylation | CX3CL1-CX3CR1 axis | 0.75 |\n| 4 | Metabolic trained immunity | mTOR-HIF1α | 0.65 |\n| 5 | APOE enhancer dysregulation | APOE transcription | 0.58 |\n| 6 | Microglial ontogeny shift | CCR2 recruitment | 0.62 |\n| 7 | LncRNA-HDAC1 complex | LncRNA-HDAC1-NF-κB | 0.48 |\n\n---\n\n**Key References for Framework:**\n- Bilbo & Schwarz (2009) for developmental origins of neuroimmune dysfunction (PMID: 19272384)\n- M. Meyer et al. for microglial ontogeny (PMID: 29909963)\n- Wendeln et al. (2018) for epigenetic microglial training (PMID: 29101263)\n- Crain et al. (2019) for MIA models and neurodevelopmental outcomes (PMID: 31134958)",
  "tokens_used": "2003",
  "persona_id": "persona-theorist"
}